Monopar Therapeutics Relocates Principal Executive Offices
Ticker: MNPR · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Feb 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-actions, filing-update
TL;DR
Monopar Therapeutics moved its HQ to Wilmette, IL.
AI Summary
Monopar Therapeutics Inc. announced on February 19, 2025, a change in its principal executive offices to 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091. This filing is a current report (8-K) under the Securities Exchange Act of 1934.
Why It Matters
A change in principal executive offices can indicate operational shifts or growth for a company. Investors should monitor if this move is associated with expansion or cost-saving measures.
Risk Assessment
Risk Level: low — This filing solely reports a change in the company's principal executive office address and does not involve financial performance, executive changes, or material business events.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- February 19, 2025 (date) — Date of earliest event reported
- 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091 (location) — New principal executive offices
FAQ
What is the new address for Monopar Therapeutics' principal executive offices?
The new address for Monopar Therapeutics' principal executive offices is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 19, 2025.
What type of SEC filing is this?
This is a Form 8-K, a Current Report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Under which state is Monopar Therapeutics incorporated?
Monopar Therapeutics Inc. is incorporated in Delaware.
What is the telephone number for Monopar Therapeutics?
The telephone number for Monopar Therapeutics, including area code, is (847) 388-0349.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding Monopar Therapeutics (MNPR).